What relation does JD Vance have with Vivek Ramaswamy? Do pharma companies have a moral responsibility to patients? And what does $300 champagne taste like?
We cover all that and more in this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. Our Washington correspondent Sarah Owermohle joins us to talk about how JD Vance, Donald Trump’s newly announced running mate, could influence health policy if Trump wins the election.
We also discuss the latest news in the biopharma industry, including the latest developments in the ongoing controversy surrounding Cassava’s Alzheimer’s drug, shortages of insulin as Novo Nordisk and Eli Lilly turn their focus toward GLP-1 drugs, and a shakeup in leadership at Gilead.
For more on JD Vance’s thoughts on health issues and his ties to the industry, go here; for more on what a Trump administration could mean for the trade group BIO, go here; for Adam’s take on the fallout at Cassava, go here; read about insulin shortages amid the GLP-1 boom here; and for more on Gilead’s leadership changes, go here.
Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect